ARISE - Advanced RNA Inhalation Solutions anchored in Evolved dry powder technology.broad
ARISE · Horizon Europe grant · 2025-04-01–2028-03-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2024-TRANSITION-01 · scheme HORIZON-EIC · topic HORIZON-EIC-2024-TRANSITIONOPEN-01. CORDIS record →
Objective
One of the main challenges in the domain of respiratory RNA delivery has been administration. Today, while 15 RNA therapeutics areundergoing clinical trials for pulmonary diseases, none has yet secured regulatory approval. Our nano-embedded microparticles(NEMs) represent a disruptive approach and paradigm shift in the field of RNA therapeutics for the treatment pulmonary diseases. OurIP-protected NEM technology comprises therapeutic RNA, which is encapsulated in lipid nanoparticles (LNPs) and formulated as aninhalable dry powder. This innovation builds the foundation to RNhale's two-pronged business concept: in-house drug developmentand RNA formulation in R&D partnerships. In brief, we have developed a standalone approach, pioneering an RNAi-based drugcandidate for the treatment of moderate and severe allergic asthma. Additionally, our scalable, and indication independentproduction technology of RNA-loaded dry powders will be a second mainstay of our commercialization strategy.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| RNhale GmbH | DE | coordinator | €2,421,499 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.